Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $441.20, moving +1.27% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.2%. Meanwhile, the Dow ...

Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

View Vertex Pharmaceuticals Incorporated VRTX stock quote prices, financial information, real-time forecasts, and company news from CNN.

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...

Vertex is pulling the plug on a treatment for a rare, inherited lung disease after the prospect caused abnormally high levels of liver enzymes in a phase 2 study. It had been testing the drug, VX-814, ...

Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. Read the latest analysis on the stock here.